Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
More News related to ABBI
- Abraxis Pharmaceutical Products (ABBI) Receives Two FDA Approvals
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Generic Camptosar Injection
- Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
- Abraxis BioScience (ABBI) Tops Q2 EPS by 5c, Revs Light
- Abraxis BioScience (ABBI) Acquires Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates from Buck Institute
Abraxis BioScience, Inc. (NASDAQ: ABBI) announced the tentative approval from FDA to market Irinotecan Hydrochloride Injection, 20 mg/mL, 2 mL, and 5 mL, the generic equivalent of Camptosar Injection manufactured by Pfizer Inc.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
